nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—breast cancer—ovarian cancer	0.758	1	CtDrD
Goserelin—LHCGR—corpus luteum—ovarian cancer	0.045	0.457	CbGeAlD
Goserelin—LHCGR—ovarian follicle—ovarian cancer	0.0352	0.358	CbGeAlD
Goserelin—LHCGR—Ovarian Infertility Genes—NR5A1—ovarian cancer	0.00332	0.177	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—INHA—ovarian cancer	0.00323	0.172	CbGpPWpGaD
Goserelin—LHCGR—gonad—ovarian cancer	0.00323	0.0328	CbGeAlD
Goserelin—LHCGR—female reproductive system—ovarian cancer	0.00289	0.0293	CbGeAlD
Goserelin—LHCGR—female gonad—ovarian cancer	0.00263	0.0267	CbGeAlD
Goserelin—LHCGR—testis—ovarian cancer	0.00233	0.0237	CbGeAlD
Goserelin—GNRHR—gonad—ovarian cancer	0.00208	0.0212	CbGeAlD
Goserelin—GNRHR—female reproductive system—ovarian cancer	0.00186	0.0189	CbGeAlD
Goserelin—LHCGR—Ovarian Infertility Genes—MLH1—ovarian cancer	0.00175	0.093	CbGpPWpGaD
Goserelin—GNRHR—female gonad—ovarian cancer	0.00169	0.0172	CbGeAlD
Goserelin—LHCGR—Ovarian Infertility Genes—PGR—ovarian cancer	0.00165	0.0881	CbGpPWpGaD
Goserelin—GNRHR—testis—ovarian cancer	0.0015	0.0152	CbGeAlD
Goserelin—LHCGR—Ovarian Infertility Genes—CCND2—ovarian cancer	0.00132	0.0705	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—MET—ovarian cancer	0.000826	0.044	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—CDKN1B—ovarian cancer	0.000601	0.032	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—EGFR—ovarian cancer	0.000418	0.0223	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HSD17B6—ovarian cancer	0.000204	0.0109	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—DLC1—ovarian cancer	0.000174	0.00925	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BCL9—ovarian cancer	0.000142	0.00754	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HSD17B6—ovarian cancer	0.000137	0.00728	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.000127	0.00675	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—DLC1—ovarian cancer	0.000116	0.00619	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—DOK1—ovarian cancer	0.000112	0.00596	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PPP1CC—ovarian cancer	0.000105	0.00561	CbGpPWpGaD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	9.92e-05	0.00529	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BCL9—ovarian cancer	9.48e-05	0.00505	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HDAC6—ovarian cancer	7.97e-05	0.00425	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PPP2R1A—ovarian cancer	7.87e-05	0.00419	CbGpPWpGaD
Goserelin—Photosensitivity reaction—Epirubicin—ovarian cancer	7.6e-05	0.000609	CcSEcCtD
Goserelin—Weight increased—Epirubicin—ovarian cancer	7.58e-05	0.000607	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—CXCL8—ovarian cancer	7.56e-05	0.00402	CbGpPWpGaD
Goserelin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	7.55e-05	0.000605	CcSEcCtD
Goserelin—Hyperglycaemia—Epirubicin—ovarian cancer	7.51e-05	0.000602	CcSEcCtD
Goserelin—Cough—Docetaxel—ovarian cancer	7.51e-05	0.000601	CcSEcCtD
Goserelin—Angina pectoris—Doxorubicin—ovarian cancer	7.5e-05	0.000601	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—DOK1—ovarian cancer	7.49e-05	0.00399	CbGpPWpGaD
Goserelin—Insomnia—Paclitaxel—ovarian cancer	7.49e-05	0.0006	CcSEcCtD
Goserelin—Pneumonia—Epirubicin—ovarian cancer	7.47e-05	0.000598	CcSEcCtD
Goserelin—Convulsion—Docetaxel—ovarian cancer	7.45e-05	0.000597	CcSEcCtD
Goserelin—Paraesthesia—Paclitaxel—ovarian cancer	7.44e-05	0.000596	CcSEcCtD
Goserelin—Hypertension—Docetaxel—ovarian cancer	7.43e-05	0.000595	CcSEcCtD
Goserelin—Drowsiness—Epirubicin—ovarian cancer	7.42e-05	0.000595	CcSEcCtD
Goserelin—Bronchitis—Doxorubicin—ovarian cancer	7.41e-05	0.000594	CcSEcCtD
Goserelin—Dyspnoea—Paclitaxel—ovarian cancer	7.38e-05	0.000592	CcSEcCtD
Goserelin—Somnolence—Paclitaxel—ovarian cancer	7.36e-05	0.00059	CcSEcCtD
Goserelin—Myalgia—Docetaxel—ovarian cancer	7.32e-05	0.000587	CcSEcCtD
Goserelin—Arthralgia—Docetaxel—ovarian cancer	7.32e-05	0.000587	CcSEcCtD
Goserelin—Chest pain—Docetaxel—ovarian cancer	7.32e-05	0.000587	CcSEcCtD
Goserelin—Nausea—Vinorelbine—ovarian cancer	7.31e-05	0.000586	CcSEcCtD
Goserelin—Renal failure—Epirubicin—ovarian cancer	7.3e-05	0.000585	CcSEcCtD
Goserelin—Dyspepsia—Paclitaxel—ovarian cancer	7.29e-05	0.000584	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	7.27e-05	0.000583	CcSEcCtD
Goserelin—Jaundice—Epirubicin—ovarian cancer	7.24e-05	0.00058	CcSEcCtD
Goserelin—Urinary tract infection—Epirubicin—ovarian cancer	7.22e-05	0.000578	CcSEcCtD
Goserelin—Dysuria—Doxorubicin—ovarian cancer	7.2e-05	0.000577	CcSEcCtD
Goserelin—Decreased appetite—Paclitaxel—ovarian cancer	7.2e-05	0.000577	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	7.2e-05	0.00383	CbGpPWpGaD
Goserelin—Dry mouth—Docetaxel—ovarian cancer	7.16e-05	0.000574	CcSEcCtD
Goserelin—Upper respiratory tract infection—Doxorubicin—ovarian cancer	7.16e-05	0.000574	CcSEcCtD
Goserelin—Fatigue—Paclitaxel—ovarian cancer	7.14e-05	0.000572	CcSEcCtD
Goserelin—Sweating—Epirubicin—ovarian cancer	7.12e-05	0.00057	CcSEcCtD
Goserelin—Pollakiuria—Doxorubicin—ovarian cancer	7.12e-05	0.00057	CcSEcCtD
Goserelin—Constipation—Paclitaxel—ovarian cancer	7.08e-05	0.000568	CcSEcCtD
Goserelin—Pain—Paclitaxel—ovarian cancer	7.08e-05	0.000568	CcSEcCtD
Goserelin—Haematuria—Epirubicin—ovarian cancer	7.08e-05	0.000567	CcSEcCtD
Goserelin—Confusional state—Docetaxel—ovarian cancer	7.08e-05	0.000567	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—YAP1—ovarian cancer	7.06e-05	0.00376	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PPP1CC—ovarian cancer	7.04e-05	0.00375	CbGpPWpGaD
Goserelin—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.03e-05	0.000564	CcSEcCtD
Goserelin—Anaphylactic shock—Docetaxel—ovarian cancer	7.02e-05	0.000563	CcSEcCtD
Goserelin—Oedema—Docetaxel—ovarian cancer	7.02e-05	0.000563	CcSEcCtD
Goserelin—Weight increased—Doxorubicin—ovarian cancer	7.01e-05	0.000562	CcSEcCtD
Goserelin—Epistaxis—Epirubicin—ovarian cancer	7e-05	0.000561	CcSEcCtD
Goserelin—Infection—Docetaxel—ovarian cancer	6.97e-05	0.000559	CcSEcCtD
Goserelin—Sinusitis—Epirubicin—ovarian cancer	6.96e-05	0.000558	CcSEcCtD
Goserelin—Hyperglycaemia—Doxorubicin—ovarian cancer	6.95e-05	0.000557	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—XIAP—ovarian cancer	6.91e-05	0.00368	CbGpPWpGaD
Goserelin—Pneumonia—Doxorubicin—ovarian cancer	6.91e-05	0.000554	CcSEcCtD
Goserelin—Shock—Docetaxel—ovarian cancer	6.91e-05	0.000553	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	6.89e-05	0.00367	CbGpPWpGaD
Goserelin—Nervous system disorder—Docetaxel—ovarian cancer	6.88e-05	0.000552	CcSEcCtD
Goserelin—Thrombocytopenia—Docetaxel—ovarian cancer	6.87e-05	0.000551	CcSEcCtD
Goserelin—Drowsiness—Doxorubicin—ovarian cancer	6.87e-05	0.00055	CcSEcCtD
Goserelin—Tachycardia—Docetaxel—ovarian cancer	6.85e-05	0.000549	CcSEcCtD
Goserelin—Feeling abnormal—Paclitaxel—ovarian cancer	6.82e-05	0.000547	CcSEcCtD
Goserelin—Skin disorder—Docetaxel—ovarian cancer	6.82e-05	0.000546	CcSEcCtD
Goserelin—Gastrointestinal pain—Paclitaxel—ovarian cancer	6.77e-05	0.000543	CcSEcCtD
Goserelin—Renal failure—Doxorubicin—ovarian cancer	6.75e-05	0.000541	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SMARCA4—ovarian cancer	6.74e-05	0.00359	CbGpPWpGaD
Goserelin—Haemoglobin—Epirubicin—ovarian cancer	6.7e-05	0.000537	CcSEcCtD
Goserelin—Jaundice—Doxorubicin—ovarian cancer	6.7e-05	0.000537	CcSEcCtD
Goserelin—Anorexia—Docetaxel—ovarian cancer	6.69e-05	0.000536	CcSEcCtD
Goserelin—Rhinitis—Epirubicin—ovarian cancer	6.68e-05	0.000535	CcSEcCtD
Goserelin—Urinary tract infection—Doxorubicin—ovarian cancer	6.68e-05	0.000535	CcSEcCtD
Goserelin—Haemorrhage—Epirubicin—ovarian cancer	6.66e-05	0.000534	CcSEcCtD
Goserelin—Hepatitis—Epirubicin—ovarian cancer	6.66e-05	0.000534	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	6.64e-05	0.00354	CbGpPWpGaD
Goserelin—Pharyngitis—Epirubicin—ovarian cancer	6.61e-05	0.00053	CcSEcCtD
Goserelin—Sweating—Doxorubicin—ovarian cancer	6.59e-05	0.000528	CcSEcCtD
Goserelin—Urinary tract disorder—Epirubicin—ovarian cancer	6.58e-05	0.000527	CcSEcCtD
Goserelin—Urticaria—Paclitaxel—ovarian cancer	6.58e-05	0.000527	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—EREG—ovarian cancer	6.58e-05	0.0035	CbGpPWpGaD
Goserelin—Oedema peripheral—Epirubicin—ovarian cancer	6.57e-05	0.000526	CcSEcCtD
Goserelin—Hypotension—Docetaxel—ovarian cancer	6.56e-05	0.000526	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	6.56e-05	0.00349	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	6.56e-05	0.00349	CbGpPWpGaD
Goserelin—Haematuria—Doxorubicin—ovarian cancer	6.55e-05	0.000525	CcSEcCtD
Goserelin—Abdominal pain—Paclitaxel—ovarian cancer	6.55e-05	0.000525	CcSEcCtD
Goserelin—Body temperature increased—Paclitaxel—ovarian cancer	6.55e-05	0.000525	CcSEcCtD
Goserelin—Urethral disorder—Epirubicin—ovarian cancer	6.53e-05	0.000524	CcSEcCtD
Goserelin—Epistaxis—Doxorubicin—ovarian cancer	6.48e-05	0.000519	CcSEcCtD
Goserelin—Sinusitis—Doxorubicin—ovarian cancer	6.44e-05	0.000516	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.4e-05	0.000513	CcSEcCtD
Goserelin—GNRHR—G alpha (q) signalling events—PIK3CA—ovarian cancer	6.36e-05	0.00339	CbGpPWpGaD
Goserelin—Insomnia—Docetaxel—ovarian cancer	6.35e-05	0.000509	CcSEcCtD
Goserelin—Paraesthesia—Docetaxel—ovarian cancer	6.3e-05	0.000505	CcSEcCtD
Goserelin—Dyspnoea—Docetaxel—ovarian cancer	6.26e-05	0.000502	CcSEcCtD
Goserelin—Somnolence—Docetaxel—ovarian cancer	6.24e-05	0.0005	CcSEcCtD
Goserelin—Eye disorder—Epirubicin—ovarian cancer	6.23e-05	0.000499	CcSEcCtD
Goserelin—Haemoglobin—Doxorubicin—ovarian cancer	6.2e-05	0.000497	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	6.19e-05	0.0033	CbGpPWpGaD
Goserelin—Cardiac disorder—Epirubicin—ovarian cancer	6.19e-05	0.000496	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—ovarian cancer	6.18e-05	0.000495	CcSEcCtD
Goserelin—Dyspepsia—Docetaxel—ovarian cancer	6.18e-05	0.000495	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—ovarian cancer	6.17e-05	0.000494	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—ovarian cancer	6.17e-05	0.000494	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PGR—ovarian cancer	6.16e-05	0.00328	CbGpPWpGaD
Goserelin—Pharyngitis—Doxorubicin—ovarian cancer	6.12e-05	0.00049	CcSEcCtD
Goserelin—Decreased appetite—Docetaxel—ovarian cancer	6.1e-05	0.000489	CcSEcCtD
Goserelin—Hypersensitivity—Paclitaxel—ovarian cancer	6.1e-05	0.000489	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—ovarian cancer	6.09e-05	0.000488	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—ovarian cancer	6.07e-05	0.000487	CcSEcCtD
Goserelin—Fatigue—Docetaxel—ovarian cancer	6.05e-05	0.000485	CcSEcCtD
Goserelin—Angiopathy—Epirubicin—ovarian cancer	6.05e-05	0.000485	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—ovarian cancer	6.04e-05	0.000484	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—ovarian cancer	6.02e-05	0.000482	CcSEcCtD
Goserelin—Pain—Docetaxel—ovarian cancer	6e-05	0.000481	CcSEcCtD
Goserelin—Constipation—Docetaxel—ovarian cancer	6e-05	0.000481	CcSEcCtD
Goserelin—Chills—Epirubicin—ovarian cancer	5.98e-05	0.000479	CcSEcCtD
Goserelin—Arrhythmia—Epirubicin—ovarian cancer	5.95e-05	0.000477	CcSEcCtD
Goserelin—Asthenia—Paclitaxel—ovarian cancer	5.94e-05	0.000476	CcSEcCtD
Goserelin—Alopecia—Epirubicin—ovarian cancer	5.89e-05	0.000472	CcSEcCtD
Goserelin—Pruritus—Paclitaxel—ovarian cancer	5.86e-05	0.00047	CcSEcCtD
Goserelin—Mental disorder—Epirubicin—ovarian cancer	5.84e-05	0.000468	CcSEcCtD
Goserelin—Erythema—Epirubicin—ovarian cancer	5.8e-05	0.000465	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—ovarian cancer	5.8e-05	0.000465	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CG—ovarian cancer	5.8e-05	0.00309	CbGpPWpGaD
Goserelin—Feeling abnormal—Docetaxel—ovarian cancer	5.78e-05	0.000464	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—ovarian cancer	5.76e-05	0.000462	CcSEcCtD
Goserelin—Gastrointestinal pain—Docetaxel—ovarian cancer	5.74e-05	0.00046	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PARP1—ovarian cancer	5.73e-05	0.00305	CbGpPWpGaD
Goserelin—Cardiac disorder—Doxorubicin—ovarian cancer	5.72e-05	0.000459	CcSEcCtD
Goserelin—Flatulence—Epirubicin—ovarian cancer	5.72e-05	0.000458	CcSEcCtD
Goserelin—Tension—Epirubicin—ovarian cancer	5.69e-05	0.000456	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	5.69e-05	0.00303	CbGpPWpGaD
Goserelin—Diarrhoea—Paclitaxel—ovarian cancer	5.67e-05	0.000454	CcSEcCtD
Goserelin—Nervousness—Epirubicin—ovarian cancer	5.63e-05	0.000452	CcSEcCtD
Goserelin—Back pain—Epirubicin—ovarian cancer	5.61e-05	0.00045	CcSEcCtD
Goserelin—Angiopathy—Doxorubicin—ovarian cancer	5.59e-05	0.000448	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—ovarian cancer	5.58e-05	0.000447	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—ovarian cancer	5.57e-05	0.000446	CcSEcCtD
Goserelin—Abdominal pain—Docetaxel—ovarian cancer	5.55e-05	0.000445	CcSEcCtD
Goserelin—Body temperature increased—Docetaxel—ovarian cancer	5.55e-05	0.000445	CcSEcCtD
Goserelin—Chills—Doxorubicin—ovarian cancer	5.53e-05	0.000443	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—ovarian cancer	5.51e-05	0.000441	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—IL6ST—ovarian cancer	5.48e-05	0.00292	CbGpPWpGaD
Goserelin—Dizziness—Paclitaxel—ovarian cancer	5.48e-05	0.000439	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—ovarian cancer	5.47e-05	0.000438	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—ovarian cancer	5.45e-05	0.000437	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—ovarian cancer	5.4e-05	0.000433	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—ovarian cancer	5.38e-05	0.000431	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—ovarian cancer	5.37e-05	0.00043	CcSEcCtD
Goserelin—Erythema—Doxorubicin—ovarian cancer	5.37e-05	0.00043	CcSEcCtD
Goserelin—Anaemia—Epirubicin—ovarian cancer	5.36e-05	0.00043	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HDAC6—ovarian cancer	5.34e-05	0.00284	CbGpPWpGaD
Goserelin—Flatulence—Doxorubicin—ovarian cancer	5.29e-05	0.000424	CcSEcCtD
Goserelin—Tension—Doxorubicin—ovarian cancer	5.27e-05	0.000422	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PPP2R1A—ovarian cancer	5.27e-05	0.00281	CbGpPWpGaD
Goserelin—Vomiting—Paclitaxel—ovarian cancer	5.27e-05	0.000422	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—PIK3CG—ovarian cancer	5.27e-05	0.0028	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	5.26e-05	0.0028	CbGpPWpGaD
Goserelin—Malaise—Epirubicin—ovarian cancer	5.23e-05	0.000419	CcSEcCtD
Goserelin—Rash—Paclitaxel—ovarian cancer	5.22e-05	0.000418	CcSEcCtD
Goserelin—Dermatitis—Paclitaxel—ovarian cancer	5.22e-05	0.000418	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—ovarian cancer	5.21e-05	0.000418	CcSEcCtD
Goserelin—Leukopenia—Epirubicin—ovarian cancer	5.19e-05	0.000416	CcSEcCtD
Goserelin—Back pain—Doxorubicin—ovarian cancer	5.19e-05	0.000416	CcSEcCtD
Goserelin—Headache—Paclitaxel—ovarian cancer	5.19e-05	0.000416	CcSEcCtD
Goserelin—Hypersensitivity—Docetaxel—ovarian cancer	5.17e-05	0.000414	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—ovarian cancer	5.16e-05	0.000414	CcSEcCtD
Goserelin—Palpitations—Epirubicin—ovarian cancer	5.13e-05	0.000411	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CD—ovarian cancer	5.1e-05	0.00272	CbGpPWpGaD
Goserelin—Cough—Epirubicin—ovarian cancer	5.06e-05	0.000406	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—ovarian cancer	5.06e-05	0.000405	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—CXCL8—ovarian cancer	5.06e-05	0.00269	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	5.04e-05	0.00268	CbGpPWpGaD
Goserelin—Asthenia—Docetaxel—ovarian cancer	5.04e-05	0.000404	CcSEcCtD
Goserelin—Convulsion—Epirubicin—ovarian cancer	5.03e-05	0.000403	CcSEcCtD
Goserelin—Hypertension—Epirubicin—ovarian cancer	5.01e-05	0.000401	CcSEcCtD
Goserelin—Ill-defined disorder—Doxorubicin—ovarian cancer	4.98e-05	0.000399	CcSEcCtD
Goserelin—Pruritus—Docetaxel—ovarian cancer	4.97e-05	0.000398	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—ovarian cancer	4.96e-05	0.000398	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—ovarian cancer	4.94e-05	0.000396	CcSEcCtD
Goserelin—Chest pain—Epirubicin—ovarian cancer	4.94e-05	0.000396	CcSEcCtD
Goserelin—Myalgia—Epirubicin—ovarian cancer	4.94e-05	0.000396	CcSEcCtD
Goserelin—Anxiety—Epirubicin—ovarian cancer	4.92e-05	0.000394	CcSEcCtD
Goserelin—Nausea—Paclitaxel—ovarian cancer	4.92e-05	0.000394	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	4.91e-05	0.000393	CcSEcCtD
Goserelin—Discomfort—Epirubicin—ovarian cancer	4.88e-05	0.000391	CcSEcCtD
Goserelin—Malaise—Doxorubicin—ovarian cancer	4.84e-05	0.000388	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—ovarian cancer	4.83e-05	0.000387	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—ovarian cancer	4.8e-05	0.000385	CcSEcCtD
Goserelin—Diarrhoea—Docetaxel—ovarian cancer	4.8e-05	0.000385	CcSEcCtD
Goserelin—Confusional state—Epirubicin—ovarian cancer	4.77e-05	0.000383	CcSEcCtD
Goserelin—Palpitations—Doxorubicin—ovarian cancer	4.74e-05	0.00038	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—ovarian cancer	4.73e-05	0.000379	CcSEcCtD
Goserelin—Oedema—Epirubicin—ovarian cancer	4.73e-05	0.000379	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—YAP1—ovarian cancer	4.72e-05	0.00252	CbGpPWpGaD
Goserelin—Infection—Epirubicin—ovarian cancer	4.7e-05	0.000377	CcSEcCtD
Goserelin—Cough—Doxorubicin—ovarian cancer	4.68e-05	0.000375	CcSEcCtD
Goserelin—Shock—Epirubicin—ovarian cancer	4.66e-05	0.000373	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—ovarian cancer	4.65e-05	0.000373	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PPP2R1A—ovarian cancer	4.65e-05	0.00248	CbGpPWpGaD
Goserelin—Nervous system disorder—Epirubicin—ovarian cancer	4.64e-05	0.000372	CcSEcCtD
Goserelin—Dizziness—Docetaxel—ovarian cancer	4.64e-05	0.000372	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—ovarian cancer	4.64e-05	0.000372	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—ovarian cancer	4.63e-05	0.000371	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—PIK3CD—ovarian cancer	4.63e-05	0.00247	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—XIAP—ovarian cancer	4.63e-05	0.00247	CbGpPWpGaD
Goserelin—Tachycardia—Epirubicin—ovarian cancer	4.62e-05	0.00037	CcSEcCtD
Goserelin—Skin disorder—Epirubicin—ovarian cancer	4.6e-05	0.000369	CcSEcCtD
Goserelin—Hyperhidrosis—Epirubicin—ovarian cancer	4.58e-05	0.000367	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—ovarian cancer	4.57e-05	0.000366	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—ovarian cancer	4.57e-05	0.000366	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—ovarian cancer	4.57e-05	0.000366	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—ovarian cancer	4.55e-05	0.000365	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.54e-05	0.000364	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—ovarian cancer	4.52e-05	0.000362	CcSEcCtD
Goserelin—Anorexia—Epirubicin—ovarian cancer	4.51e-05	0.000362	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SMARCA4—ovarian cancer	4.51e-05	0.0024	CbGpPWpGaD
Goserelin—Dry mouth—Doxorubicin—ovarian cancer	4.47e-05	0.000358	CcSEcCtD
Goserelin—Vomiting—Docetaxel—ovarian cancer	4.46e-05	0.000358	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CB—ovarian cancer	4.44e-05	0.00237	CbGpPWpGaD
Goserelin—Rash—Docetaxel—ovarian cancer	4.43e-05	0.000355	CcSEcCtD
Goserelin—Hypotension—Epirubicin—ovarian cancer	4.42e-05	0.000355	CcSEcCtD
Goserelin—Dermatitis—Docetaxel—ovarian cancer	4.42e-05	0.000354	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—ovarian cancer	4.42e-05	0.000354	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—EREG—ovarian cancer	4.4e-05	0.00235	CbGpPWpGaD
Goserelin—Headache—Docetaxel—ovarian cancer	4.4e-05	0.000352	CcSEcCtD
Goserelin—Oedema—Doxorubicin—ovarian cancer	4.38e-05	0.000351	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—ovarian cancer	4.38e-05	0.000351	CcSEcCtD
Goserelin—Infection—Doxorubicin—ovarian cancer	4.35e-05	0.000349	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.31e-05	0.000346	CcSEcCtD
Goserelin—Shock—Doxorubicin—ovarian cancer	4.31e-05	0.000345	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—ovarian cancer	4.3e-05	0.000344	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—ovarian cancer	4.29e-05	0.000344	CcSEcCtD
Goserelin—Insomnia—Epirubicin—ovarian cancer	4.28e-05	0.000343	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—ovarian cancer	4.28e-05	0.000343	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—CXCL8—ovarian cancer	4.27e-05	0.00227	CbGpPWpGaD
Goserelin—Skin disorder—Doxorubicin—ovarian cancer	4.26e-05	0.000341	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—ovarian cancer	4.25e-05	0.000341	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—ovarian cancer	4.24e-05	0.000339	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—ovarian cancer	4.22e-05	0.000338	CcSEcCtD
Goserelin—Somnolence—Epirubicin—ovarian cancer	4.21e-05	0.000337	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—ovarian cancer	4.18e-05	0.000335	CcSEcCtD
Goserelin—Nausea—Docetaxel—ovarian cancer	4.17e-05	0.000334	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—ovarian cancer	4.17e-05	0.000334	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PGR—ovarian cancer	4.13e-05	0.0022	CbGpPWpGaD
Goserelin—Decreased appetite—Epirubicin—ovarian cancer	4.12e-05	0.00033	CcSEcCtD
Goserelin—Hypotension—Doxorubicin—ovarian cancer	4.09e-05	0.000328	CcSEcCtD
Goserelin—Fatigue—Epirubicin—ovarian cancer	4.08e-05	0.000327	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—IL2—ovarian cancer	4.08e-05	0.00217	CbGpPWpGaD
Goserelin—Pain—Epirubicin—ovarian cancer	4.05e-05	0.000324	CcSEcCtD
Goserelin—Constipation—Epirubicin—ovarian cancer	4.05e-05	0.000324	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—PIK3CB—ovarian cancer	4.03e-05	0.00215	CbGpPWpGaD
Goserelin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.99e-05	0.00032	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—ovarian cancer	3.96e-05	0.000318	CcSEcCtD
Goserelin—Paraesthesia—Doxorubicin—ovarian cancer	3.93e-05	0.000315	CcSEcCtD
Goserelin—Dyspnoea—Doxorubicin—ovarian cancer	3.91e-05	0.000313	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—ovarian cancer	3.9e-05	0.000313	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—ovarian cancer	3.89e-05	0.000312	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CG—ovarian cancer	3.88e-05	0.00207	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CXCL8—ovarian cancer	3.88e-05	0.00207	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Epirubicin—ovarian cancer	3.87e-05	0.00031	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—ovarian cancer	3.86e-05	0.000309	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PARP1—ovarian cancer	3.84e-05	0.00204	CbGpPWpGaD
Goserelin—Decreased appetite—Doxorubicin—ovarian cancer	3.81e-05	0.000305	CcSEcCtD
Goserelin—Fatigue—Doxorubicin—ovarian cancer	3.78e-05	0.000303	CcSEcCtD
Goserelin—Urticaria—Epirubicin—ovarian cancer	3.76e-05	0.000301	CcSEcCtD
Goserelin—Constipation—Doxorubicin—ovarian cancer	3.75e-05	0.0003	CcSEcCtD
Goserelin—Pain—Doxorubicin—ovarian cancer	3.75e-05	0.0003	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—ovarian cancer	3.74e-05	0.0003	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—ovarian cancer	3.74e-05	0.0003	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—IL2—ovarian cancer	3.71e-05	0.00197	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TERT—ovarian cancer	3.69e-05	0.00197	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6ST—ovarian cancer	3.67e-05	0.00195	CbGpPWpGaD
Goserelin—Feeling abnormal—Doxorubicin—ovarian cancer	3.61e-05	0.000289	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.58e-05	0.000287	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CG—ovarian cancer	3.52e-05	0.00188	CbGpPWpGaD
Goserelin—Hypersensitivity—Epirubicin—ovarian cancer	3.49e-05	0.00028	CcSEcCtD
Goserelin—Urticaria—Doxorubicin—ovarian cancer	3.48e-05	0.000279	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—ovarian cancer	3.46e-05	0.000278	CcSEcCtD
Goserelin—Body temperature increased—Doxorubicin—ovarian cancer	3.46e-05	0.000278	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CAV1—ovarian cancer	3.41e-05	0.00182	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CD—ovarian cancer	3.41e-05	0.00182	CbGpPWpGaD
Goserelin—Asthenia—Epirubicin—ovarian cancer	3.4e-05	0.000272	CcSEcCtD
Goserelin—Pruritus—Epirubicin—ovarian cancer	3.35e-05	0.000268	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—ESR1—ovarian cancer	3.29e-05	0.00175	CbGpPWpGaD
Goserelin—Diarrhoea—Epirubicin—ovarian cancer	3.24e-05	0.00026	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL6ST—ovarian cancer	3.24e-05	0.00172	CbGpPWpGaD
Goserelin—Hypersensitivity—Doxorubicin—ovarian cancer	3.23e-05	0.000259	CcSEcCtD
Goserelin—Asthenia—Doxorubicin—ovarian cancer	3.14e-05	0.000252	CcSEcCtD
Goserelin—Dizziness—Epirubicin—ovarian cancer	3.13e-05	0.000251	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PPP2R1A—ovarian cancer	3.11e-05	0.00166	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—APC—ovarian cancer	3.11e-05	0.00166	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CG—ovarian cancer	3.11e-05	0.00166	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—NRAS—ovarian cancer	3.11e-05	0.00166	CbGpPWpGaD
Goserelin—Pruritus—Doxorubicin—ovarian cancer	3.1e-05	0.000248	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CD—ovarian cancer	3.1e-05	0.00165	CbGpPWpGaD
Goserelin—Vomiting—Epirubicin—ovarian cancer	3.01e-05	0.000241	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—ovarian cancer	3e-05	0.00024	CcSEcCtD
Goserelin—Rash—Epirubicin—ovarian cancer	2.99e-05	0.000239	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—ovarian cancer	2.98e-05	0.000239	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—MAPK3—ovarian cancer	2.98e-05	0.00159	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CB—ovarian cancer	2.97e-05	0.00158	CbGpPWpGaD
Goserelin—Headache—Epirubicin—ovarian cancer	2.97e-05	0.000238	CcSEcCtD
Goserelin—Dizziness—Doxorubicin—ovarian cancer	2.9e-05	0.000232	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—CXCL8—ovarian cancer	2.86e-05	0.00152	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—MAPK1—ovarian cancer	2.83e-05	0.00151	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—EGFR—ovarian cancer	2.83e-05	0.00151	CbGpPWpGaD
Goserelin—Nausea—Epirubicin—ovarian cancer	2.81e-05	0.000225	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—ovarian cancer	2.79e-05	0.000223	CcSEcCtD
Goserelin—Rash—Doxorubicin—ovarian cancer	2.76e-05	0.000221	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—ovarian cancer	2.76e-05	0.000221	CcSEcCtD
Goserelin—Headache—Doxorubicin—ovarian cancer	2.74e-05	0.00022	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CD—ovarian cancer	2.73e-05	0.00146	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2—ovarian cancer	2.73e-05	0.00146	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—ovarian cancer	2.71e-05	0.00144	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CB—ovarian cancer	2.7e-05	0.00144	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—KRAS—ovarian cancer	2.68e-05	0.00143	CbGpPWpGaD
Goserelin—Nausea—Doxorubicin—ovarian cancer	2.6e-05	0.000209	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—CXCL8—ovarian cancer	2.6e-05	0.00138	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL2—ovarian cancer	2.48e-05	0.00132	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TERT—ovarian cancer	2.47e-05	0.00132	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—ovarian cancer	2.46e-05	0.00131	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ERBB2—ovarian cancer	2.42e-05	0.00129	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CB—ovarian cancer	2.38e-05	0.00127	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MTOR—ovarian cancer	2.38e-05	0.00127	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCL8—ovarian cancer	2.29e-05	0.00122	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CAV1—ovarian cancer	2.29e-05	0.00122	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—HRAS—ovarian cancer	2.28e-05	0.00121	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN1B—ovarian cancer	2.24e-05	0.00119	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—ovarian cancer	2.21e-05	0.00118	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ESR1—ovarian cancer	2.2e-05	0.00117	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CASP3—ovarian cancer	2.19e-05	0.00117	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL2—ovarian cancer	2.19e-05	0.00117	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6—ovarian cancer	2.18e-05	0.00116	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6ST—ovarian cancer	2.17e-05	0.00115	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCND1—ovarian cancer	2.13e-05	0.00114	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CTNNB1—ovarian cancer	2.11e-05	0.00113	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—APC—ovarian cancer	2.08e-05	0.00111	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CG—ovarian cancer	2.08e-05	0.00111	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—NRAS—ovarian cancer	2.08e-05	0.00111	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MMP9—ovarian cancer	2.07e-05	0.0011	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTEN—ovarian cancer	2.06e-05	0.0011	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AKT1—ovarian cancer	2.01e-05	0.00107	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—MAPK3—ovarian cancer	1.99e-05	0.00106	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—MAPK1—ovarian cancer	1.9e-05	0.00101	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—EGFR—ovarian cancer	1.9e-05	0.00101	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VEGFA—ovarian cancer	1.86e-05	0.000991	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT3—ovarian cancer	1.84e-05	0.000981	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NRAS—ovarian cancer	1.84e-05	0.000979	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CD—ovarian cancer	1.83e-05	0.000975	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—ovarian cancer	1.81e-05	0.000966	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—KRAS—ovarian cancer	1.79e-05	0.000955	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK3—ovarian cancer	1.76e-05	0.000937	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MYC—ovarian cancer	1.71e-05	0.000912	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK1—ovarian cancer	1.67e-05	0.000892	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EGFR—ovarian cancer	1.67e-05	0.000892	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—ovarian cancer	1.65e-05	0.000877	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ERBB2—ovarian cancer	1.62e-05	0.000861	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MTOR—ovarian cancer	1.6e-05	0.00085	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CB—ovarian cancer	1.6e-05	0.00085	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KRAS—ovarian cancer	1.58e-05	0.000842	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL8—ovarian cancer	1.53e-05	0.000817	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—HRAS—ovarian cancer	1.52e-05	0.000811	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN1B—ovarian cancer	1.5e-05	0.000798	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—ovarian cancer	1.48e-05	0.000789	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CASP3—ovarian cancer	1.47e-05	0.000782	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL2—ovarian cancer	1.47e-05	0.000781	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6—ovarian cancer	1.46e-05	0.000777	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—ovarian cancer	1.45e-05	0.000774	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCND1—ovarian cancer	1.43e-05	0.000761	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CTNNB1—ovarian cancer	1.41e-05	0.000754	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—ovarian cancer	1.41e-05	0.000749	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MMP9—ovarian cancer	1.39e-05	0.000739	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTEN—ovarian cancer	1.38e-05	0.000734	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AKT1—ovarian cancer	1.35e-05	0.000717	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HRAS—ovarian cancer	1.34e-05	0.000716	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL6—ovarian cancer	1.29e-05	0.000685	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	0.000663	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT3—ovarian cancer	1.23e-05	0.000657	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NRAS—ovarian cancer	1.23e-05	0.000655	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKT1—ovarian cancer	1.19e-05	0.000632	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK3—ovarian cancer	1.18e-05	0.000628	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MYC—ovarian cancer	1.15e-05	0.00061	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK1—ovarian cancer	1.12e-05	0.000597	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGFR—ovarian cancer	1.12e-05	0.000597	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KRAS—ovarian cancer	1.06e-05	0.000564	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—ovarian cancer	9.73e-06	0.000518	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—ovarian cancer	9.41e-06	0.000501	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HRAS—ovarian cancer	9e-06	0.000479	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6—ovarian cancer	8.61e-06	0.000459	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT1—ovarian cancer	7.95e-06	0.000423	CbGpPWpGaD
